A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy - Expansion Study
National University Hospital, Singapore
200 participants
Nov 11, 2022
INTERVENTIONAL
Conditions
Summary
The study conducted on cancer patients is designed to test safety and efficacy of limb hypothermia in cancer patients using the new Paxman Limb Cryocompression System (PLCS). Ultimately this will lead to the development of a therapy regime that will help to prevent chemotherapy-induced neuropathy in cancer patients.
Eligibility
Inclusion Criteria4
- Age 21- 80 years.
- Signed informed consent from patient or legal representative
- Scheduled to receive weekly paclitaxel chemotherapy
- Patients may receive other chemotherapy drugs alongside taxane e.g. Platinum/Herceptin.
Exclusion Criteria4
- Open skin wound or ulcers of the limbs
- History of Raynaud's phenomenon, peripheral vascular disease, or poorly controlled diabetes
- Pregnant woman
- A score of more than 5 in Total Neuropathy Score (TNS) at baseline for cancer patients
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles. Cryocompression will be applied during every cycle of chemotherapy for a duration of up to 4 hours. All chemotherapy patients will receive 30 minutes pre-infusion cooling and 30 minutes post-infusion cooling. Cryocompression for each cycle will not exceed 4 hours. Chemotherapy and concomitant limb cryocompression are performed for 12 cycles and may be continued further in consultation with the PI. Overall, limb cryocompression will be administered for no longer than four hours.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05606068